Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges

Company Overview - Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm focused on therapies for rare muscular and neurological conditions [1] - The company's portfolio includes three main products: Firdapse, Agamree, and Fycompa [1] - Firdapse is the core product, indicated for Lambert-Eaton Myasthenic Syndrome (LEMS) [1] Product Details - Firdapse is specifically designed for the treatment of LEMS, a rare autoimmune disorder [1] - The company aims to address unmet medical needs in the rare disease space with its specialized therapies [1]